Isomorphic Labs raised $5 billion in a Series C funding round co-led by Greenoaks and Sequoia Capital, with participation from Andreessen Horowitz and Alphabet. The financing comes three and a half months after Demis Hassabis stepped down as CEO of Google DeepMind, which he co-founded before Google acquired the lab in 2014. The funds will support AI-driven drug development, including foundational biology models and therapeutic programs moving toward clinical trials. Drug discovery startups raised $23.2 billion in 2026, a record according to Dealroom, amid advances in AI and increased investment by companies such as OpenAI and Anthropic. Isomorphic previously raised $2.1 billion in a Series B round in May.
Source: Read the original article


